# OnCo record selpercatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/selpercatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "selpercatinib" ;
  schema:name "Selpercatinib"@en ;
  schema:description "Selpercatinib is a selective RET inhibitor approved for any tumour with a RET fusion, with a further label update in July 2026."@en ;
  schema:url <https://onco.cc/drugs/selpercatinib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Selpercatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q96405266> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Selpercatinib>, <https://www.nice.org.uk/guidance/ta911>, <https://www.nice.org.uk/guidance/ta1042> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (RET)" ;
  schema:alternateName "Retevmo" ;
  onco:approval "US 2020: RET-fusion NSCLC and thyroid; RET-mutant MTC", "US 2022: RET-fusion solid tumours (tumour-agnostic)", "US 2026: Label update (July 2026)", "EU 2021: EU brand Retsevmo", "England (NICE) 2023: Untreated RET fusion-positive advanced non-small-cell lung cancer", "England (NICE) 2025: Previously treated RET fusion-positive advanced non-small-cell lung cancer not previously treated with a RET inhibitor" ;
  onco:acceleratedApproval "US 2020-05-08: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy *", "US 2020-05-08: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) *", "US 2020-05-08: Adult patients with metastatic RET fusion-positive Non-Small Cell Lung Cancer (NSCLC)", "US 2022-09-21: Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options *", "US 2024-04-10: Formulation: Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy", "US 2024-04-10: Formulation: Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)", "US 2024-04-10: Formulation: Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options" ;
  onco:acceleratedApprovalConfirmed "US 2022-09-21: Adult patients with metastatic RET fusion-positive Non-Small Cell Lung Cancer (NSCLC)", "US 2024-06-12: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) *", "US 2024-06-12: Formulation: Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)", "US 2024-09-27: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy *", "US 2024-09-27: Formulation: Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy", "US 2026-07-14: Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options *", "US 2026-07-14: Formulation: Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options" ;
  onco:related <https://onco.cc/biomarkers/ret-fusion/> ;
  onco:cancers <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/medullary-thyroid-cancer/>, <https://onco.cc/cancers/papillary-thyroid-cancer/>, <https://onco.cc/cancers/ret-fusion-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ret/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:terms <https://onco.cc/terms/cancer-drugs-fund/> ;
  onco:trials <https://onco.cc/trials/nct03157128/>, <https://onco.cc/trials/nct04280081/>, <https://onco.cc/trials/nct03899792/>, <https://onco.cc/trials/nct04819100/>, <https://onco.cc/trials/libretto-431/> .